• Researcher Profile

    Joseph H. Antin, MD

     
    Joseph H. Antin, MD

    Top Doctor

     
    Chief and Program Director, Stem Cell Transplantation
    Institute Physician


    Professor of Medicine, Harvard Medical School

    Center/Program

    Hematologic Oncology

    Office phone: 617-632-2525
    Fax: 617-632-5175
    Email: joseph_antin@dfci.harvard.edu

    Preferred contact method: email

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Hematologic Malignancies

    Interests

    Stem cell/bone marrow transplantation, Aplastic anemia, Paroxysmal nocturnal hemoglobinuria (PNH), Bone marrow failure, Graft-versus-host disease and Graft-versus-leukemia

    Area of Research

    Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1B58
    Boston, MA 02215

    Biography

    Dr. Antin received his MD from Cornell University in 1978, and postgraduate training in hematology and medical oncology at DFCI and Brigham and Women's Hospital. He subsequently served as director of the Bone Marrow Transplantation Service at BWH from 1987 to 1997. He now heads the Stem Cell Transplant Program of the Department of Medical Oncology at DFCI and BWH. He is a founding member and past president of the American Society of Blood and Marrow Transplantation and a past Chairman of the Steering Committee of the BMT Clinical Trial Network.

    Research

    Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect

    The biology of acute graft-versus-host disease (GVHD) must be considered in the context of a host that has been injured by the underlying disease, conditioning regimen, and infection. These factors result in an environment that supports and sustains the clinical syndrome of acute GVHD through induction of inflammatory mediators such as chemokines, adhesion molecules, cytokines, and cellular effectors. If this cycle can be interrupted, GVHD might be ameliorated. Thus we are studying novel regimens to control GVHD, through both cellular engineering and application of new immunosuppressants, including sirolimus and denileukin diftitox.

    A second related interest is to understand and harness the graft-versus-leukemia (GVL) effect. Previous efforts to control GVHD, such as T cell depletion, have resulted in loss of GVL effect. Inhibition of inflammatory cytokines may result in reductions in GVHD with sparing of GVL effect. Furthermore, we have shown that we can use GVL effect to induce remissions in relapsed patients, but at the risk of inducing GVHD. We are studying whether the limitations of T cell depletion can be overcome with the judicious use of donor lymphocytes preemptively administered after transplantation. We are also assessing whether GVL effect can be harnessed to allow a reduction in transplantation conditioning and its associated toxicity.

    Investigators

    • Cutler, Corey, MD
    • Ho, Vincent, MD
    • Koreth, John, MBBS, DPhil
    • Armand, Philippe, MD
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now